微生物组特征及其在葡萄膜炎中的作用:发病机制、诊断与治疗前景
非感染性葡萄膜炎受遗传、免疫和环境因素影响,黏膜微生物组(包括肠道、口腔和眼表微生物群落)通过肠-眼轴调节全身和眼部免疫反应。本综述整合宏基因组学、代谢组学及体内外实验证据,归纳免疫失衡、抗原模拟、上皮屏障破坏和细菌易位四种机制,并提出微生物组指导的诊断与治疗策略。
要点
- 肠道、口腔和眼表黏膜微生物组通过肠-眼轴影响葡萄膜炎的发病与表型。
- 普雷沃菌属和粪杆菌属等特定分类群及短链脂肪酸等代谢物与眼部炎症相关。
- HLA-B27和HLA-A29等位基因影响微生物组组成和疾病表型,提示基因-微生物组-免疫三元交互。
核心结论
- 微生物组通过免疫失衡、抗原模拟、上皮屏障破坏和细菌易位四种机制在葡萄膜炎发病中起关键作用。
- 基于微生物组的策略(如合理益生菌设计、饮食调节和靶向微生物治疗)有望补充现有免疫抑制方案。
- 将微生物组科学转化为临床实践需要稳健的多组学研究、纵向队列、机制研究和精准指导的干预试验。
研究设计与样本
- 本综述整合宏基因组学、代谢组学、体外和体内实验及小鼠模型的研究证据,并结合作者研究项目的发现。
主要发现
- 微生物组失调改变肠道屏障功能,扰乱T细胞稳态,驱动可突破眼免疫豁免的全身免疫激活。
- 普雷沃菌属和粪杆菌属等特定分类群以及短链脂肪酸等微生物代谢物被牵涉于促进或减轻眼部炎症。
- HLA-B27和HLA-A29等位基因影响微生物组组成和疾病表型,提示基因-微生物组-免疫三元交互。
临床怎么用
- 作者认为,合理益生菌设计、饮食调节和靶向微生物治疗等微生物组指导策略有望补充现有免疫抑制方案。
局限性
- 将微生物组见解转化为临床实践需要稳健的多组学研究、纵向队列、机制研究和精准指导的干预试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-infectious uveitis is a group of complex inflammatory eye diseases shaped by genetic susceptibility, immune dysregulation, and environmental cues. Among these, the mucosal microbiome-including gut, oral, and ocular surface microbial communities-has emerged as a key player in modulating systemic and ocular immune responses. Recent evidence supports a gut-eye axis wherein microbial dysbiosis alters intestinal barrier function, perturbs T cell homeostasis, and drives systemic immune activation that can breach ocular immune privilege. Specific taxa, such as Prevotella and Faecalibacterium, as well as microbial metabolites including short-chain fatty acids, have been implicated in promoting or mitigating ocular inflammation. Human leukocyte antigen (HLA) alleles, notably HLA-B27 and HLA-A29, influence both microbiome composition and disease phenotype, suggesting a gene-microbiome-immunity triad of interaction in uveitis pathogenesis. Drawing on insights from metagenomics, metabolomics, in vitro and in vivo experimental and murine models, this review delineates four key mechanisms-immune imbalance, antigenic mimicry, epithelial barrier disruption, and bacterial translocation-that underpin the key roles of microbiome in uveitis. We combine current literature and integrate findings from our research programs to highlight diagnostic and therapeutic opportunities. Microbiome-informed strategies, such as rational probiotic design, dietary modulation, and targeted microbial therapies, hold promise for complementing existing immunosuppressive regimens. Translating these insights into clinical practice requires robust multi-omic studies, longitudinal cohorts, mechanistic studies, and precision-guided intervention trials. By framing uveitis within a mucosal immunological context, this review proposes a future precision medicine roadmap for integrating microbiome science into ocular inflammatory disease management.
引用
- Agrawal K, Hong ASY, Cifuentes-González C, et al. Microbiome signatures and their role in uveitis: Pathogenesis, diagnostics, and therapeutic perspectives. Prog Retin Eye Res. 2025. PMID: 41077176. doi:10.1016/j.preteyeres.2025.101409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。